Residues within processed protein fragments bound to major histocompatibility complex class I (MHC-I) glycoproteins have been considered to function as a series of "independent pegs" that either anchor the peptide (p) to the MHC-I and/or interact with the spectrum of αβ-T-cell receptors (TCRs) specific for the pMHC-I epitope in question. Mining of the extensive pMHC-I structural database established that many selfand viral peptides show extensive and direct interresidue interactions, an unexpected finding that has led us to the idea of "constrained" peptides. Mutational analysis of two constrained peptides (the HLA B44 restricted self-peptide (B44DPα-EEFGRAFSF) and an H2-D b restricted influenza peptide (D b PA, SSLENFRAYV) demonstrated that the conformation of the prominently exposed arginine in both peptides was governed by interactions with MHC-I-orientated flanking residues from the peptide itself. Using reverse genetics in a murine influenza model, we revealed that mutation of an MHC-I-orientated residue (SSLENFRAYV → SSLENARAYV) within the constrained PA peptide resulted in a diminished cytotoxic T lymphocyte (CTL) response and the recruitment of a limited pMHC-I specific TCR repertoire. Interactions between individual peptide positions can thus impose fine control on the conformation of pMHC-I epitopes, whereas the perturbation of such constraints can lead to a previously unappreciated mechanism of viral escape.
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crystal structure | cytotoxic T cell | MHC class I | viral immunity | epitope M ajor histocompatibility complex class I (MHC-I) molecules bind processed peptide (p) fragments (1) within a defined cleft. A conserved hydrogen-bonding network at the N and C termini often, although not exclusively (2) , limits the length of bound peptides to 8-10 amino acids, with the specificity of binding being mediated via peptide side chains that interact with six pockets (A to F) within the MHC-I cleft. The extensive polymorphism that characterizes the MHC is largely a function of diversity within the cleft providing the structural basis for a broad spectrum of peptides to bind different MHC-I glycoproteins. The size, hydrophobicity, and electrostatic charge of these pockets impacts the potential peptide repertoire of different MHC-I allotypes by enforcing a marked preference for "anchor residues" at certain positions within a given peptide. For example, P2-Glu and PΩ-Tyr (the C-terminal residue) are the dominant anchor residues for HLA-B44 (3), whereas P5-Asn and PΩ-Met/Leu/Ile represent the anchor motif for H2-D b (4) . In addition amino acids at other secondary positions can also influence allele-specific binding (5) . Presently, the conceptual perspective for MHC-I-bound peptides is that they align in a linear and extended fashion, with some side chains pointing down to interact with the MHC (anchor residues), while others point up to form potential T-cell receptor (TCR) contact points. Moreover, each residue within the peptide is thought to act as an independent peg and consequently there is considered to be no interplay between the residues within any given peptide. The functional analysis of alanine-scanning mutations of MHC-I restricted peptides relies on this interpretation, which is also the assumption underlying programs that seek to predict immunogenicity.
Immune CD8+ cytotoxic T lymphocytes (CTLs) express αβ-TCRs that recognize pMHC-I complexes. Despite pathogen complexity, CTL responses are often directed against few of the many potential pMHC-I complexes (6) . This skewing of effective antiviral immunity to immunodominant peptides puts selective pressure on the virus with the consequence that CTL escape mutants may arise during infection. For example, mutations in dominant viral peptides have been reported to subvert CTL recognition following infection with hepatitis B virus (7) , HIV type 1 (HIV-1) (8) , and Epstein-Barr virus (EBV) (9) . Such mutations may impact on (i) the conformation and flexibility of the bound peptide and alter signaling, as observed for the immunodominant peptide from vesicular stomatitis virus (VSV) (10) ; (ii) MHC-I binding due to the removal of critical anchor residue interactions; (iii) TCR recognition directly; and (iv) proteosomal cleavage (11) . Moreover, mutations within viral proteins can lead to the generation of altered peptide ligands (APLs), including T-cell antagonists (7) . What precisely dictates CTL escape is not fully established (10) , although maintenance of viral fitness is a key parameter that can limit the capacity of the virus to mutate functionally conserved residues in an immunogenic peptide, thus limiting the molecular potential for immune evasion.
To accommodate extensive pMHC-I diversity, the host possesses a diverse T-cell repertoire generated via somatic rearrangement of gene segments found within the TCRα (TRAV, IMGT nomenclature) and TCRβ (TRBV) gene loci. Although pathogen-specific TCR diversity appears to be of key importance in protective immunity (12, 13) , there are examples of TCR bias in antiviral immunity, including Epstein-Barr virus (EBV) (14) and influenza A virus (15) . A number of different mechanisms may engender TCR bias (reviewed in refs. 16, 17) , including the pMHC-I structural landscape (18) (19) (20) . Given the importance of understanding immune repertoire selection, mechanisms of viral escape and pMHC-I structure in the design of peptide-based vaccines, we mined the large database of pMHC-I structures to systematically explore the way in which peptides bind to the MHC-I. Surprisingly, we found a large number of MHC-I restricted peptides displaying distinct modes of interaction between residue positions that constrain their conformations. We identified three categories of structural constraints, highlighting the diverse mechanisms by which MHC-oriented peptide residues can simultaneously impact on the conformations of positions important for TCR recognition. Our study provides a conceptual framework for assessing the extent and nature of conformational interdependence that can arise between the residues of MHC-I bound peptides.
Results pMHC Conformation Is Dependent on Intrapeptide Contacts. The general view is that MHC-I bound peptide side chains adopt conformations independent of each other to interact with the MHC or serve as potential TCR contact points. However, we noted that the conformation of an endogenous, high-affinity DPα peptide (EEF-GRAFSF) bound to HLA-B*4402 (B44) and its closely related allomorphs (3) is characterized by a conserved pattern of intrapeptide side-chain interactions. When in complex with the HLA B44 allomorphs, DPα adopts a constrained conformation within its central region. Namely, the prominently surface-exposed side chain of P5-Arg is supported via interactions with the MHC-orientated, flanking aromatic rings of P3-Phe and P7-Phe (Fig. 1A) .
We evaluated the degree to which the B44-DPα conformation was dependent on side-chain interactions within DPα itself by solving the pMHC-I structures of five alanine-scan mutants of the peptide (F3A, R5A, F7A, F3AR5A, and R5AF7A) (Fig. 1, Fig. S1 , and Table S1 ). All structures were solved in the same space group, were isomorphous to each other, and the peptides are free from crystal contacts. Thus any conformational changes observed can be attributed to the specific mutation within the peptide. The conformation of the B44 Agbinding cleft, which constitutes the MHC-I component of the B44-DPα epitope, is conserved between the index B44-DPα structure and each of the five APL complexes (rmsd 0.36-0.61 Å; Fig. S1A ). Moreover, alanine substitution of the position P5-Arg (R5A; Fig. 1C ) had little effect on the overall peptide conformation when compared to that of the index peptide. In contrast, significant changes in peptide conformation were observed in those variants where the flanking phenylalanines were mutated ( Fig. 1 B and D-F) . In the B44-DPα-F7A structure the P5-Arg side chain has "flipped" toward the space previously occupied by the P7-Phe aromatic ring (Fig. 1D) , whereas in the B44-DPα-F3A structure, the overall peptide conformation had significantly changed with the side chain of P5-Arg becoming disordered ( Fig. 1B and Fig. S1B ). The loss of intrapeptide interactions between P3-Phe, P5-Arg, and P7-Phe, as observed in the F3A/R5A and R5A/F7A double mutants, also caused the remaining phenylalanine in each case to change conformation. For example, in the B44-DPα-F3A-R5A complex, the aromatic ring of P7-Phe shifted significantly with respect to the index peptide and exhibited greater mobility ( Fig. 1E and Fig. S1E ). Overall, APL structures displaying the greatest changes in peptide conformation were those with substitutions at P3-Phe enabling the central region of the peptide to shift down toward the base of the antigen binding cleft (maximum deviation in the peptide backbone of up to 2.8 Å; Fig. 1 B and E) . Substitution of P7-Phe resulted in less dramatic changes in peptide conformation, whereas the substitution of P5-Arg had little effect. Thus P3-Phe and, to a lesser extent, P7-Phe appear to fix the P5-Arg residue in a constrained position, while also stabilizing their respective conformations. The net consequence of altering these stabilizing interactions is that the structural landscape of the pMHC-I complex is also changed giving a different epitope.
Constrained Peptides and the pMHC-I Database. To assess the commonality of constrained peptides, we analyzed the pMHC-I entries in the protein structure database (Research Collaboratory for Structural Bioinformatics-Protein Database, RCSB-PDB). As of July 2009, the PDB contained 251 pMHC-I crystal structure entries including 214 binary complexes (Fig. S2A) . A total of 103 of the binary pMHC-I entries were excluded from our analyses due to crystal contacts formed by the bound peptides.
Of the remaining 111 entries all but 3 (1A9B, 3.2 Å; 1E28, 3.0 Å; and 1P1Z, 3.26 Å) have been determined to a resolution higher than 3.0 Å and consist of 87 unique antigenic peptide sequences, bound to 22 different MHC alleles (Table S2 ). Ten structures were found to have been duplicated at higher resolution and were thus considered redundant. The remaining 101 unique pMHC-I complexes comprised our sample population and were examined for peptide selfconstraints. We were able to identify three "constraint" categories ( Fig. 2A) , each characterized by a distinct set of readily identifiable structural features (Fig. 2 B-D) . The three categories (types I, II, and III) are defined below, accompanied by typical examples from the database. A definition of "unconstrained" peptides is also given: Unconstrained peptides. We were surprised during the course of our analysis to find some form of interresidue interaction in nearly all of the peptides examined, including contacts either between main chain atoms of adjacent residues or between the side chain of a given position and the peptide bond atoms immediately either side of it. Although these ubiquitous intrapeptide contacts were discounted during our analysis, we identified a subset of pMHC-I structures (approximately a third of the total analyzed) in which additional interactions were restricted to predominantly van der Waals (vdw) contacts between a side chain at a given position (n) and the main chain atoms of the residues no further than n − 2 and n + 2 (although occasional isolated side chain to side chain interactions were also observed in some of these structures). The positions within these peptides can be considered to act as independent pegs. Peptides displaying these structural characteristics were classed as unconstrained peptides (Fig. 2) , an example of which is the structure of a 9-mer peptide derived from MART-1 in complex with HLA-A*0201 [2GUO (21); Fig. 2E ]. Within the category of unconstrained peptides are also included pMHC-I structures displaying either (i) more than one distinct backbone conformation, as seen in the B*1501/UbcH6 and B*3508/pp65 complexes [1XR9 (22) and 3BWA (23), respectively], or (ii) significant disorder along their backbones, as in the case of two EBV 11-mer peptides in complex with HLA-B*35 [2FYY (24) and 2NW3 (25) ]. The mobility of the peptides observed in these structures is most likely a reflection of an inherent flexibility in their MHC-I-bound states and is thus consistent with the absence of conformational constraints, either self-imposed or MHC-I induced. In summary, 34 "unconstrained" peptides were identified, accounting for 34% of the analyzed pMHC-I entries. "Type I" constrained peptides. The HLA-B44-bound DPα peptide represents an archetypal example of a self-constrained peptide (Fig.  1A) , characterized by a central solvent exposed residue (n), the side chain of which forms a network of interactions with the side chains of two flanking residues at positions n + 2 and n − 2. Another characteristic example within this category, designated type I, is the HLA-A*0201 restricted p1049 peptide [ALWGFFPVL; 1B0G (26) ], where the prominently surface-exposed side chain of P5-Phe is constrained by P3-Trp and P7-Pro (Fig. 2B ). This peptide has been shown to elicit a well-defined T-cell response that is dependant on P5-Phe. An analog of the p1049 peptide, designated p1058 (FAPGFFPYL), has also been characterized structurally and biologically [1I7R (27) ]: p1058 adopts a conformation equivalent to p1049 within the Ag-binding cleft of HLA-A2 (rmsd <0.55 Å for peptide main chain atoms), the only exception being the side chain of P5-Phe, which has an altered conformation consistent with a loss of type I constraints due to the presence of a P3-proline instead of a tryptophan. Importantly, p1058 has been shown to be antagonistic for p1049/HLA-A2-specific CTL function, with the effect being reversed by a P3W substitution in p1058. In total, 10% of eligible pMHC structures analzyed exhibited type I constraints ( Fig. 2A) . "Type II" constrained peptides. These peptides are also characterized by a solvent accessible position (n), the conformation of which is constrained via interactions with the side chains of two or more side chains. In contrast to type I peptides, however, we noted that these peptides do not display any restrictions on the relative positioning of the residues involved in the constraints. Moreover, in many of these peptides only one of the constraining residues contacts the side chain of n, whereas the other is involved in main chain interactions with n. An example of a peptide classed as type II, is the HLA-B*0801 restricted 8-mer derived from HIV-1 GAG protein p17 [GGKKKYKL; 1AGD (28) ], in which the highly solvent exposed side chain of P4-Lys forms vdw and hydrogen bond interactions with P6-Tyr, while its main chain interacts with P3-Lys (Fig.  2C ). In summary, 29% of eligible pMHC-I entries exhibited type II constraints. "Type III" constrained peptides. Within type III constrained peptides there are at least two flanking residues constraining a central solvent exposed feature (n), consisting of one or more residues itself. However, in contrast to types I and II constraints, these flanking residues interact predominantly with each other, and to a lesser extent, with the backbone of the central constrained feature. No interactions occur with the side chain(s) of n. Although type III constraints are observed in peptides of canonical length, such as the 8-mer H-2K b restricted HSV glycoprotein B-derived peptide, SSIEFARL [1T0M (29)], they best characterize longer (bulged) pMHC-I peptides. Indeed, 6 of the 8 unique 11-14-mers sampled in our analysis were found to exhibit type III constraints. A 13-mer determinant from EBV (LPEPLPQGQL-TAY), for instance, binds to HLA-B*3501 and HLA-B*3508 in a near-identical bulged and rigid conformation (rmsd of 0.625 Å for all peptide atoms), in which the P6-Pro is observed packing against the main chain and side chain of P10-Leu [ Fig. 2D ; 1ZHK, 1ZHL (30) ]. Importantly, although only the backbones of P6-Pro and P10-Leu were observed interacting with the SB27 TCR in the ternary complex structure [2AK4 (18) ], substitution of P6-Pro to glycine results in a marked reduction in TCR binding, indicating that maintenance of the conformation of this loop is critical for achieving a sufficient TCRpMHC-I interaction (18) . In summary, a total of 28 pMHC-I entries were assigned to the type III constraints category, representing 28% of the structures analyzed (25% of sampled peptide sequences).
Example Where Loss of Intrapeptide Constraints Resulted in
Compromised Antigenicity. During our analysis we noted several examples where changes in epitope immunogenicity were linked to amino acid substitutions that disrupted intrapeptide contacts. This suggested that targeting residues that stabilize conformations of potential TCR contact residues might represent a unique mechanism for viral escape from CTL-mediated immunity. Variants of the HLA-B*0801 (B8) restricted 8-mer derived from HIV-1 p17 [GGKKKYKL; 1AGD (28)], a type II constrained peptide, represent elegant examples of this mechanism. In addition to the index p17 peptide, the structure of four naturally occurring variants that abrogate recognition by p17-specific CTL have also been solved (28) . In the case of the B8p17-K3R variant (1AGB), mutation of the MHC-I-oriented P3-Lys was found to result in subtle but significant changes in peptide conformation. These changes are focused on the predicted TCR contact P4-Lys (all atom rmsd >0.76 Å), which is constrained by interactions with P3-Lys and P6-Tyr in both the index peptide and the two P7-Lys variants (1AGC and 1AGE; Fig. 2C ). Importantly, the conformational changes observed in the K3R variant are accompanied by a loss of all stabilizing H-bonds involving P4-Lys, suggesting that the diminished recognition by HLA-B8/p-17-specific CTL for this variant can be attributable to compromised intrapeptide constraints. Similarly, we previously solved the structure of a H2-D b (D b ) restricted influenza peptide derived from the acid polymerase subunit 1 protein (PA 224 , SSLENFRAYV) that displays type II constraints [1YN6 (19) ] similar to those identified for the HIV-1 p17 peptide. The conformation of the PA 224 peptide bound to H2-D b is characterized by a pronounced C-terminal arch centered on the critical TCR contact, P7-Arg (Fig. S3 A-C) . P7-Arg interacts via its side chain and main chain with the MHC-oriented aromatic rings of P6-Phe and P9-Tyr, respectively. Notably, alanine substitution of either P7-Arg or P6-Phe abrogates D b PA 224 -specific CTL recognition (19) without influencing pMHC-I stability (Fig. S4 ). Given the low solvent accessibility of P6-Phe compared to P7-Arg, we proposed that mutations at P6 might alter TCR binding to the pMHC-I indirectly, by influencing the conformation of P7-Arg. To evaluate this, we determined the crystal structure of the H2-D b -PA-F6A complex (Fig. S3 D-F ) and compared it to that of the wild-type (WT) epitope (Fig. 3A) . We found that whereas the structure of the Ag-binding cleft and backbone configuration of the peptide are very similar in both structures, the D b PA-F6A structure displays a significantly different P7-Arg side chain conformation with respect to the index peptide.
To evaluate the functional consequence of the F6A mutation on D b PA 224 -specific CTL recognition, we used reverse genetics to generate recombinant influenza A viruses where PA 224 (31) was disrupted in its normal location and replaced by inserting the wild-type PA 224 or PA-F6A peptides into the neuraminidase (NA) stalk of A/ Puerto Rico/34/1 (32), referred to as either the NA-PA and NA-F6A viruses, respectively. Both the wild-type NA-PA and the mutant NA-F6A replicated to equivalent titers in vitro (1.58 ± 1.9 × 10 8 pfu and 1.09 ± 0.8 × 10 9 pfu/mL, respectively), suggesting these alterations had no impact on viral fitness.
As expected, a robust D b PA 224 -specific CTL response was observed in mice infected with the NA-PA virus and the responding T cells did not bind the D b PA-F6A tetramer (Fig. 3B) . Whereas substantial numbers of D b PA-specific CTLs were found in the bronchoaveolar lavage (BAL) (17.9%) and spleen (2.76%) of mice infected with the NA-PA virus (Fig. 3C) , the D b PA-F6A CTL counts (BAL, 2%, P < 0.01; spleen, 0.25%, P < 0.01) from those given NA-F6A ( (Fig. S5B ) epitopes supporting the notion that both viral fitness and antigen load in vivo was equivalent for these two viruses. To exclude the possibility that the diminished F6A-specific CTL response observed in NA-F6A infected mice was due to a defect in processing/ presentation, mice were immunized with the PA or F6A peptides emulsified in CFA and the spleen was harvested 7 days later for analysis ( + T cells (Fig. 3D) . Overall, this suggests that mutation of the P6-Phe disrupts the constrained nature of the P7-Arg, resulting in a pMHC-I-conformation that is both poorly immunogenic and noncross reactive for the WT D b PA epitope.
Discussion
The general view has been that immunogenic peptides bind MHC-I in a linear and extended manner, with the peptide residues pointing "up" or "down" and acting independently of each other. Our analysis of peptide conformations within the pMHC-I structural database indicates that this is not necessarily the case. We estimate that >50% of pMHC-I epitopes exhibit self-constraints, in which the conformation and/or positioning of one or more amino acids in the peptide is influenced by the residues flanking it. We defined three types of constrained interactions (types I, II, and III): Types I and II constraints were generally represented by pMHC-I structures that involved presentation of peptides with shorter lengths (8-10 aa), whereas type III constraints were more apparent for longer (≥10 aa) peptides. We formally demonstrated the interdependence of side-chain conformations within constrained peptides by examining the conformations of a self-peptide bound to HLA-B*4402 and an influenza peptide bound to H2-D b . In each case, removal of an MHC-orientated residue specifically impacted on the conformation of a flanking, upwardpointing residue that is available for direct TCR recognition. Moreover, a number of examples of constrained peptides in the pMHC-I database exhibited similar conformational sensitivities to mutations within these constrained regions of the peptide.
There was no consistent correlation between a given MHC allele and the imposed constraints within the bound peptide. Furthermore, we found no particular amino acid biases that were universally characteristic for any given category of constrained peptide, although proline residues (present in 48% of the peptide sequences sampled) were overrepresented within the type I classification (71%). The fact that prolines apply significant torsional limitations on the peptide backbone makes them an obvious candidate for imposing selfconstraints. The clearest example to date of proline constraints in an MHC-I restricted peptide whose structure has been solved is the 9-mer IRAAPPPLF derived from the signal sequence of cathepsin A (34) . The frequency of prolines in immunogenic peptides is likely to reflect that certain MHC-I alleles, notably the HLA B7 supertype, exhibit specificity for a P2-Pro anchoring motif. Moreover, prolinecontaining peptides are less readily digestible by the aminopeptidase trimming enzymes in the endoplasmic reticulum (35) .
Although the type of constraint is dependent on the peptide sequence, the structural characteristics of the MHC-I molecule will also be a determining factor. For example, the HLA-B35 restricted 11-mer peptide (HPVGEADYFEY) complexed to HLA-B*3501 [2FYY (24) ] is partially disordered, but it is well ordered and displays type III constraints when bound to HLA-B*3508 [2FZ3 (24) ]. As such, the same, potentially immunogenic peptide can be presented to the available T-cell repertoire as topographically distinct structures. Thus, MHC-I polymorphism ensures that a range of peptides are presented by imposing MHC allele-specific intrapeptide constraints, with the consequence that a diversity of immunogenic structures is presented to the immune system of any one individual (potentially six different MHC-I alleles). The net result is that the "antigenic surface" that can be recognized throughout any given population is greatly enhanced (36) .
Our hypothesis that pMHC-I complexes can be modified via differing constraints on peptide binding offers enhanced and unexpected possibilities for viral escape that do not necessarily reflect any direct change in the residues recognized directly by the TCR. PA-F6A pMHC-I complex appears to be attributable to the increased mobility of the P7-Arg, thereby making this epitope a more difficult target for the available naïve T-cell repertoire.
In conclusion, rather than taking the position that each amino acid within an antigenic peptide functions effectively as an independent entity, our study has defined patterns of intrapeptide interaction that constrain overall structure, and thus antigenicity, for a large number of pMHC-I complexes. This idea of constrained peptides has implications for both peptide prediction programs and for attributing specific roles to particular amino acid residues, as judged by the functional analysis of alanine-scanning mutations. The importance of these constrained interactions is reinforced when considering that "nonobvious" peptide variations can result in the total or partial compromise of immunogenicity. As we move toward the design and improvement of vaccine strategies, an appreciation of such constraints is key for the assessment and selection of peptide targets that function to limit viral escape from TCR/pMHC-I mediated immune control.
Materials and Methods
Database Mining. A list of deposited pMHC-I structures was obtained by searching the RCSB-PDB and subsequently consolidated by cross-referencing against entries listed in the MGT/3Dstructure-DB. Coordinates and, where available,electrondensitymapsweredownloadedfromthePDBusingCOOT (37) . Interresidue atomic contacts were identified by applying a cut-off distance of 4.0 Å. Intrapeptide interactions were further evaluated using the COOT implementation of REDUCE and PROBE, thus permitting visualization of the presence and extent of vdw interactions between peptide positions. In the case of structures containing multiple peptide copies within the asymmetric unit, intrapeptide interactions were accepted as legitimate when observed in all copies.
Synthetic Peptides. Peptides were purchased from Auspep. In general, peptides were supplied as a lyophilized powder at a purity greater than 80%. Peptides were stored at 4°C and solubilized at 100 mg/mL in DMSO before use.
Preparation of Recombinant MHC-Peptide Complexes. Recombinant HLA-B*4402 heavy chain (residues 1-274), H-2D
b heavy chain (residues 1-274), murine and human β 2 m were expressed separately as inclusion bodies in Escherichia coli as previously described (3, 19) . Correctly folded pMHC complexes were purified by anion exchange and size exclusion chromatography. Protein was buffer exchanged into Tris-HCl (pH 8.0), 150 mM NaCl and concentrated to 3-9 mg/mL for crystallization trials.
Crystallization and Data Collection. (i) HLA-B*4402/DPα variant complexes:
Crystals of each of the five complexes were grown at 20°C using the hanging drop vapor diffusion method. In each case, the protein was mixed with an equal volume of the reservoir buffer (12-30% PEG 4000, 0.1 M trisodium citrate dihydrate (pH 5.2-5.7), 0.2 M ammonium acetate) and incubated over a 1-mL reservoir. Before data collection, crystals were flash-frozen using 10% glycerol as a cryoprotectant. All data sets were collected at 100 K both in-house on an R-Axis IV++ detector and at the BioCars beamline (Advanced Photon Source) using a Quantum 4 CCD detector. peptide from influenza A virus acid polymerase has been previously reported (19) (1YN6). Crystals of H-2D b /PA224-F6A were grown by hanging drop vapor diffusion at 20°C, by mixing an equal volume of protein (9 mg/mL) and reservoir solution, containing 100 mM sodium citrate, pH 5.6, 0.2 M ammonium acetate, and 25% PEG 4000. Before data collection, crystals were cryoprotected against reservoir solution containing 10% glycerol (vol/vol) and flash-frozen at 100 K.
Structure Determination and Refinement. (i) HLA-B*4402/DPα variant complexes: The five B44DPα variant structures were determined by molecular replacement using previously published coordinates of HLA-B*4402 as a search model [PDB code 1M6O (3)]. All structures were initially subjected to simulated annealing and coordinate/ADP refinement followed by iterative cycles of model building and refinement using COOT and programs within CCP4 (38) . In the case of the F3A/R5A and R5A/F7A structures, the final ADP refinement in PHENIX, followed by the REFMAC5 implementation of TLS parameterization. Validation was carried out using programs within CCP4i.
(ii) H-2D b /PA224 F6A complex: The structure was solved by molecular replacement using previously deposited H-2D b coordinates as a starting model (3CC5).
Structure refinement and validation was carried out in COOT, MOLPROBITY, and programs within CCP4i. A summary of data collection, refinement, and validation statistics for all structures are presented in Table S1 .
Mice, Viruses, and Viral Infection. Female C57BL/6J (B6, H-2 b ) mice were bred in the animal facility of the Department of Microbiology and Immunology at the University of Melbourne and were held under specific pathogen-free conditions. Naïve mice were infected either intranasally (i.n.) with 10 2 PFU or intraperitonally (i.p.) with 10 7 PFU of recombinant A/PR8/34 (H1N1) influenza viruses as previously described (32) . The recombinant influenza viruses were generated using an eight-plasmid reverse genetics system (31 
Consideration of MHC-I Restricted Peptides Involved in Crystal
Contacts. In 101 of the binary complexes the peptides were found to be participating in symmetry related (i.e., crystal) contacts. The effect of such contacts on peptide conformation is a matter of debate, although in our experience it can vary in severity from negligible to moderate, depending on the extent of the contacts and the groups that are involved (e.g., main chain vs. side chain).
ThePDBprovideshighlyillustrativeexamplesoftherangeofcrystal contact-mediatedeffects onpeptide conformationin the form ofthree binary pMHC-I structures 1I7R, 1HHK, and 3BEW. The first two are HLA-A*0201/9-mer structures, each consisting of two pMHC copies per ASU. In both structures the peptide environment varies slightly between the two copies. Whereas in one copy the peptide is not involved in crystal contacts, in the second a peptide side chain forms a single contact with a symmetry-related molecule. In both structures, the two copies adopt near identical conformations with an rmsd for all peptide atoms of <0.19 Å. A similar change in peptide environment between the two copies of the BF2*2101/10-mer complex in entry 3BEW, on the other hand, is accompanied by significant side-chain differences (rmsd of 1.2 Å for all peptide atoms). The most striking example, however, is that of a HLA-Cw*0401/9-mer binary complex (1QQD) and its KIR2DL1 ternary counterpart (1IM9). The peptide adopts equivalent conformations in the binary and ternary complex (rmsd of 0.33 Å and 0.67 Å for main chain and all peptide atoms, respectively), although some significant side-chain shifts are observed. The 1IM9 structure, however, also consists of a second pMHC-I copy in the ASU that is not part of a ternary complex. The peptide in this molecule forms extensive crystal contacts with the α-3 domain of a symmetry-related pMHC-I and as a result displays significant shifts along its backbone with respect to the peptide conformation observed in the binary structure (main chain and all atoms rms deviations of 0.84 Å and 1.26 Å, respectively).
In addition to the large conformational changes described in the cases above, it should be generally accepted that crystal contacts can often lead to otherwise flexible, solvent exposed peptide side chains, appearing in a single, well-ordered conformation. As such groups were to be the main targets of this analysis, we chose to eliminate from our sample population all binary pMHC-I entries displaying peptide-mediated crystal contacts (≤4.0 Å). In the case of structures consisting of more than one pMHC molecule in the ASU, only peptide copies not involved in crystal contacts were analyzed.
Impact of MHC-I Allelic Variation on the "Constrained" Nature of Bound Peptides. The structure of the 11-mer EBV peptide HP-VGEADYFEY has been solved in complex with B*3501 (2FYY), in which it appears partially disordered, as well as B*3508 (2FZ3), in which it is well ordered and displays "type III" constraints. These differences in peptide conformation can be accounted for fully in terms of the HLA polymorphism at residue 156, which in the B*3508 structure has the effect of stabilizing one of the two main flanking residues (P5-Glu) that constrain the central bulge of the peptide.
Two other peptides, the synthetic 9-mer GRFAAAIAK and the EBV-derived 10-mer APQPAPENAY, were assigned to the type II constraints category based on their conformation when in complex with HLA-B*2705 (1JGE) and HLA-B*3501 (2AXG), respectively. Yet, these same peptides were found to display type III constraints in the context of HLA-B*2709 (1K5N) and HLA-B*3508 (2AXF), respectively. Moreover, the HSV glycoprotein B-derived 8-mer SSIEFARL was found displaying type III constraints in the context of H2Kb (1T0M), but was unconstrained in the context of H2Kb m8 (1RJY). In all cases, the differences observed in the conformation and constraints displayed by the peptides can be accounted for by the HLA polymorphisms.
These four cases of MHC-dependent changes in peptide constraints account for 33% of the peptide sequences that were analyzed in the context of two or more MHC alleles (12 peptides in total) and provide clear evidence of the overriding importance that MHC sequence can have on peptide conformation in certain cases.
Role of pMHC-I Epitope Constraints on TCR Recognition and Binding.
Given the small number of examples available for analysis, the role of peptide "self-constraints" in the interaction between MHC-bound peptide and TCR cannot be determined. Cases were identified in our analysis where constrained peptides either retained their binary complex conformation upon ligation or underwent conformational change (see below). It is worth noting, however, that where the conformation of a constrained peptide was conserved between its binary and ternary structures, the constraining interactions observed in the binary pMHC complex were often lost, indicating than the conformation of these peptides "relaxes" upon TCR ligation. These observations suggest that constraints may only serve to promote initial recognition by the cognate TCR, while subsequently allowing conformational changes to take place that are necessary for complete docking of the pMHC to the TCR. Type I. The HLA-A*0201 restricted p1049 peptide (ALWGFFPVL; 1B0G), displays type I constraints, as the prominently surfaceexposed side chain of P5-Phe is constrained by P3-Trp and P7-Pro (Fig. 2B) . Interestingly, p1049 maintains its binary complex conformation upon ligation with the AHIII TcR (1LP9), with an rmsd between the two structures <0.36 Å for all peptide atoms, although binding to the TCR is accompanied by a partial loss of intrapeptide constraints. In three additional ternary complexes between AHIII and p1049 bound to HLA-A*0201 variants containing alanine substitutions in the Ag-binding cleft-K66A (2J8U), T163A (2UWE), and W167A (2JCC)-the peptide conformation is again conserved with respect to its binary structure (all atom rmsd <0.5 Å). Moreover, in the ternary complex of the K66A mutant (2J8U), the type I constraints of p1049 are also maintained. The HLA-A*0201 restricted GILGFVFTL peptide derived from influenza matrix protein, also displays type I constraints, as the conformation of the P5-Phe side chain is constrained by P3-Leu and P7-Phe (2VLL). HLA-A*0201 GILGFVFTL has also been solved in ternary complex with the JM22 TCR (1OGA, 2VLJ, and 2VLK), and JM22-S99A mutant (2VLR), at different resolutions and in different space groups. The conformation of the peptide observed in the binary complex is also conserved in each of the ternary complexes (rmsd < 0.37 Å for all peptide atoms), whereas the type I constraints are also maintained in the two higher resolution ternary complexes (1OGA and 2VLJ). Type II. In the case of the HTLV-1 TAX derived peptide LLFGYP-VYV bound to HLA*0201 (2AV7), binding to either the B7 (1BD2) or A6 (1AO7) TCR is accompanied by large conformational rearrangements centered on P6-Pro (all atoms rmsd >1.59 Å). Despite these movements, P6-Pro and P3-Phe are able to maintain the type II constraints on P5-Tyr in the ternary complexes. Type III. The conformation adopted by the 13-residue (LPEPL-PQGQLTAY) determinant from EBV when bound to HLA-B*3508 alone is also maintained in its ternary complex with the SB27 TcR (2AK4), with an average rmsd for all peptide atoms of 0.75 Å, although the interaction between P6-10 and P10-Leu is not conserved. The conformation of the H2K b restricted 8-mer KVITFIDL (pKB1 peptide; 1KJ3) also remains relatively fixed upon ligation by the KB5-C20 TcR (all atom rmsd <0.58 Å), whereas the H2K bm8 restricted endogenous pBM8 peptide (2CLV; SQYYYNSL) undergoes a significant conformational change upon binding to the BM3.3 TCR (2OL3; all atom rmsd of 1.3 Å), although without loss of constraints.
Correlation Between Constraint and Immunogenicity. By characterizing antigenic peptides as being unconstrained in their pMHCbound states, no assumptions are made about their relative immunogenicity, which varies significantly between peptides assigned to this category. The HLA-B*3501-restricted 11-mer EPLPQGQLTAY peptide derived from the BZLF1 antigen of Epstein-Barr virus displays an unconstrained conformation in the binary structure (1ZSD). Nevertheless, the HLA-B*3501/ EPL complex generates a significant CTL response in EBV-infected individuals, even though the structure of its ternary complex with the ELS4 TCR (2NX5) has shown that the peptide adopts a significantly altered conformation upon TCR docking. The unconstrained HLA-B*2705 restricted RRIYDLIEL peptide derived from EBV is also reported as being immunodominant (2BSR), as is the HLA-A*0201 restricted 9-mer (AAGIGILTV) derived from MART-1 (2GUO; Fig. 3F ). By contrast, the A2L mutant of that MART-1 peptide (2GTZ), which is also unconstrained, displays a greatly reduced, or abolished CTL response.
Our analysis of published pMHC-I structures led to the identification of a number of instances where alterations in peptide constraints, and subsequent changes in pMHC-I topology, correlated with loss of pMHC-I antigenicity. However, the introduction of constraints in a peptide (and the increase inpeptide rigidity implied by this) does not necessarily correlate with greater immunogenicity. The B*3501 restricted 14-mer LPAVVGLSPGEQEY derived from an alternative reading frame of M-CSF (1XH3), displays a helical conformation between positions 9 and 12. In addition to the characteristic helical main chain hydrogen bonding network present within this region, the peptide is stabilized by multiple vdw and hydrogen bonding interactions involving main chain and side chain groups between positions P5-Val and P13-Glu. Despite the large number of constraining interactions, this peptide is marked by considerable flexibility in its central region. By contrast, two variants of this peptide containing a single alanine substitution at position P2-Pro and a double alanine substitution at P2-Pro and P9-Pro, were shown to display significant positional differences between positions P4 and P12 with respect to the index peptide, although the two maintain a helical conformation between P9 and P12. Moreover, introduction of each mutation was correlated with a decrease in flexibility with respect to the index peptide, which in turn was accompanied by a decrease in immunogenicity. Thus, the P2A mutant, displaying intermediate flexibility, acted as a weak agonist, whereas the P2A/P9A, being the most rigid of the three peptides, completely abrogated the T-cell response. These findings demonstrate that single amino acid changes in a highly constrained peptide can have significant effects on its MHC-bound conformation and that decreased peptide flexibility is not necessarily consistent with greater immunogenicity. b PA-F6A was solved in space group P4 3 2 1 2 and consists of one molecule in the asymmetric unit. Clear electron density for the backbone and side chains of the MHC molecule was observed throughout the modeled structure. The SSLENAR-AYV peptide adopts an extended conformation and forms anchoring interactions with the α1-α2 domains at the peptide positions P2-Ser (Tyr7, Tyr45, and Glu163 of the H-2D b heavy chain), P5-Asn (Gln70, Trp73, and Gln97), and P10-Val (Ser77, Leu81, and Trp147). Additionally there are vdw contacts between the MHC molecule and the side chain of P1-Ser (Lys68 and Glu163), and the backbone at P4-Glu (His155), P6-Ala (Tyr156 and Trp173), and P9-Tyr (Lys146 and Trp147). The region of the peptide between P6-Ala and P9-Tyr extends prominently from the peptide-binding groove and is significantly solvent exposed. This includes the site of the P6-Phe to P6-Ala mutation and the neighboring P7-Arg.
To directly compare the crystal structure of the F6A mutant to the wild-type H2D b PA structure, some investigation was carried out regarding the differences in the peptide conformation between the two published structures available in the PDB (1YN6 and 1WBY). In 1WBY, the prominent P7-Arg in the peptide forms a salt-bridging interaction with P4-Glu of the peptide. This means that the side chain of the arginine has moved away from P6-Phe where it has a significant interaction surface in the alternative structure, 1YN6. Upon downloading electron density maps from the Uppsala EDS, the picture was not made any clearer as the P7-Arg side chain had broken density past the Cγ in 1WBY. Furthermore there were no maps available for 1YN6. As the structure of H2D b PA was solved in this laboratory, a refinement could be carried out using archived data files. This also ensured that an identical strategy to the mutant F6A structure could be used to provide a fair comparison.
From the archived H2D b PA data files, exactly the same steps were carried out as for the F6A mutant-data processing with HKL2000, molecular replacement by PHASER, model building in COOT 0.5, and restrained refinement followed by TLS refinement in REFMAC5. The final statistics for this refinement were R work = 19.2% and R free = 25.2% (Table S1 ). This is comparable to the published structure, and the validation statistics from MOLPROBITY are as good as those obtained for the F6A structure. Density maps clearly show that the P7-Arg of the peptide is in the conformation seen in 1YN6, forming vdw interactions with P6-Phe.
Comparing the F6A structure and the wild-type H2-D b PA structure that has been refined in the same manner, there is little movement between the α1 and α2 domains of the MHC molecule (rmsd 0.3 Å over residues 1-180 of the α-chain, at the Cα position). The two peptides adopt equivalent conformations, overlaying with an rmsd of 0.16 Å at the Cα position, with identical anchoring interactions to the MHC molecules. The major difference between the two structures occurs at the solvent-exposed C-terminal region of the F6A mutant peptide. The absence of the phenylalanine side chain present in the wild-type epitope is compensated for by the presence of an additional water molecule and a slight movement in the side chain of Glu41 from the HC of a neighboring symmetry-related molecule. The side chain of P7-Arg is shifted significantly in the F6A structure compared to the wild type, where it forms a number of vdw interactions with the aromatic side chain of the neighboring phenylalanine. In the absence of these stabilizing interactions the arginine side chain has relatively shifted toward the N-terminal end of the peptide. In this new position it forms vdw interactions with the side chain of symmetry-related Glu41, as well as the main chain at Glu41 and Ala40 of the neighboring heavy chain. The magnitude of the movement of the side chain is such that the guandinium head group of P7-Arg has moved by 8.5Å, with the overlaid side chains forming an angle of 100°from the equivalent positions of the Cα atom.
Thermostability assay. The thermostability of recombinant MHC/ peptide complexes was assessed using circular dichroism (CD). CD spectra were measured on a Jasco 810 spectropolarimeter using a thermostatically controlled cuvettete at temperatures between 35°C and 70°C as described in detail elsewhere (1) . Far-UV spectra from 195 to 250 nm were collected and averaged over two individual scans; measurements for the thermal melting experiments were made at intervals of 0.1°C at a rate of 1°C/ min. The midpoint of thermal denaturation (Tm) for each protein was calculated by taking the first derivative of the ellipticity data and identifying the inflection point.
Structure Analysis and Figure Generation . All structures were analyzed using COOT version 0.6-pre. Coordinate files were edited using the CCP4i implementation of PDBSET. Root mean square deviation (rmsd) calculations and molecular contact analysis were carried out using LSQKAB and CONTACT, respectively. Molecular contacts were further analyzed and visualized using the COOT implementation of REDUCE and PROBE. All figures were generated using PyMOL. In the case of B-E in Fig. 2 , images were initially generated using the COOT implementation of RAS-TER3D and then imported into PyMOL. PA-F6A cells were recovered from the spleen on d9 and sorted using a FACSAria and processed as described in Materials and Methods. M, individual mice tested; BV, IMGT nomenclature for TCRVβ gene segments. The TRBV13-1 repertoire was analyzed from CD8+F6A+ cells sorted from spleen on day 9 after infection, as described in Materials and Methods.
